BRKR Quote, Financials, Valuation and Earnings

Azenta has a net margin of 4.73% compared to Bruker's net margin of -2.93%. Bruker's return on equity of 19.61% beat Azenta's return on equity of -7.49%.

Bruker has a consensus price target of $74.01, signalling upside risk potential of 26.25%. On the other hand Azenta has an analysts' consensus of -- which suggests that it could grow by 13.2%. Given that Bruker has higher upside potential than Azenta, analysts believe Bruker is more attractive than Azenta.

Bruker has a beta of 1.170, which suggesting that the stock is 16.959% more volatile than S&P 500. In comparison Azenta has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.482%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.34%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 6.88% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $864.4M, which are larger than Azenta quarterly revenues of $170.1M. Bruker's net income of $40.9M is higher than Azenta's net income of -$5M. Notably, Bruker's price-to-earnings ratio is 28.18x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 2.68x versus 4.06x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of 4.73% compared to Bruker's net margin of -728.57%. Bruker's return on equity of 19.61% beat Bionano Genomics's return on equity of -158.95%.

Bruker has a consensus price target of $74.01, signalling upside risk potential of 26.25%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 246.74%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

Bruker has a beta of 1.170, which suggesting that the stock is 16.959% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.220, suggesting its more volatile than the S&P 500 by 121.987%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.34%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 6.88% of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $864.4M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Bruker's net income of $40.9M is higher than Bionano Genomics's net income of -$44.2M. Notably, Bruker's price-to-earnings ratio is 28.18x while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 2.68x versus 0.40x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 4.73% compared to Bruker's net margin of -21.86%. Bruker's return on equity of 19.61% beat Harvard Bioscience's return on equity of -20.42%.

Bruker has a consensus price target of $74.01, signalling upside risk potential of 26.25%. On the other hand Harvard Bioscience has an analysts' consensus of $6.25 which suggests that it could grow by 196.21%. Given that Harvard Bioscience has higher upside potential than Bruker, analysts believe Harvard Bioscience is more attractive than Bruker.

Bruker has a beta of 1.170, which suggesting that the stock is 16.959% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.945%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.34%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 6.88% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $864.4M, which are larger than Harvard Bioscience quarterly revenues of $22M. Bruker's net income of $40.9M is higher than Harvard Bioscience's net income of -$4.8M. Notably, Bruker's price-to-earnings ratio is 28.18x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 2.68x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Singular Genomics Systems has a net margin of 4.73% compared to Bruker's net margin of -4136.7%. Bruker's return on equity of 19.61% beat Singular Genomics Systems's return on equity of -54.24%.

Bruker has a consensus price target of $74.01, signalling upside risk potential of 26.25%. On the other hand Singular Genomics Systems has an analysts' consensus of -- which suggests that it could fall by -35.92%. Given that Bruker has higher upside potential than Singular Genomics Systems, analysts believe Bruker is more attractive than Singular Genomics Systems.

Bruker has a beta of 1.170, which suggesting that the stock is 16.959% more volatile than S&P 500. In comparison Singular Genomics Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.34%. Singular Genomics Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 6.88% of its earnings as a dividend. Singular Genomics Systems pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $864.4M, which are larger than Singular Genomics Systems quarterly revenues of $406K. Bruker's net income of $40.9M is higher than Singular Genomics Systems's net income of -$16.8M. Notably, Bruker's price-to-earnings ratio is 28.18x while Singular Genomics Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 2.68x versus 18.09x for Singular Genomics Systems. Usually stocks with elevated PS ratios are considered overvalued.